Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
GAITHERSBURG, Md., April 13, 2016 -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Bill Enright, Chief Executive Officer, will participate in a vaccine development panel at the Annual Regional Biotech Forum. The panel will take place in Gaithersburg, MD on April 19, 2016 at 9:30 AM ET.
The panel, titled “Advancements in Vaccine Development,” will be moderated by Dr. Ripley Ballou, Vice President & Head of Global Vaccines at GlaxoSmithKline. Mr. Enright will discuss Altimmune’s innovative approaches to vaccine development and how vaccine development is leading the way in the regional push to become the third largest biotech cluster in the United States.
About Altimmune
Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system.
The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.
Contacts: Bill Enright President and CEO Phone: 240-654-1450 Email: [email protected] Investor Relations Stephanie Carrington ICR, Inc. Phone: 646-277-1282 Email: [email protected]
